U.S. Markets close in 5 hrs 48 mins

Adverum Biotechnologies, Inc. (ADVM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.3950+0.0350 (+1.48%)
As of 10:12AM EDT. Market open.
Sign in to post a message.
  • g
    gh
    So frustrating to see that it is just irrationally to have these prices.... i am not an experienced investor, but ADVM:
    1. felt down from 10 to 4 in APR because of the bad side effects of the DME treatment;
    2. has 400M cash and 40M debt only; at burn rate of 100M per year - 4years ahead are safe;
    3. has only 100M shares, i.e. cash per share is 4$ today;
    4. the 3y low is just under 3$; seems like now, at 2.3$ we are now at a ATL price;
    5. they still have a working product 022, in progress; they also have a sold licence (see pipeline on their web).

    What do I miss ladies and gentlemen? I got tired of averaging down...
  • q
    qi
    Please see what Zacks said on June 25 when ADVM was $3.82. "Adverum Biotechnologies (ADVM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices." OMG, dropped to $2.26 today (-69%) in just 0ne month
  • J
    John
    this is one for your buy & hodl, set n forget portion of your portfolio. just a matter of time. #willing2wait
  • A
    Anonymous
    Great news! Buy more!!! Bio ETF just loaded with 3,5 mill more shares
  • P
    Paul W
    Looking at recent exec changes, anyone know why this co. needs a chief marketing officer?
  • A
    Anonymous
    If they won’t use that DME anymore, means they take care of patients health. They should be up, not down.
  • q
    qi
    No matter what, ADVM is absolutely undervalued. Market value ($331m) is lower than cash in hand ($404m). Stock price ($3.16) is lower than book value ($4.26). ADVM-22 is under investigating but this may not be a bad thing. I bought more and hold.
  • s
    stocktargetadvisor
    $ADVM
    Maintains Chardan Capital Neutral USD 5 » USD 3
    Downgraded by Goldman Sachs USD 2.51
    Downgrades Cantor Fitzgerald Neutral USD 23 » USD 3
    Maintains SVB Leerink Market Perform USD 5 » USD 2
  • J
    John
    Awesome, an ideal "set and forget " just picked a boatload, thank you very much
  • D
    DonD
    It’s doing the limbo now🤦‍♂️
    Bullish
  • M
    Mr. Market
    Again, this stock is a hidden gem. Simply, NO one knows about it ! So much beaten down. Current SP is sitting now at 80% less than its IPO price. Cash on hand is more than its market cap. Great technology and very advanced pipeline. Annual market size is over $10B. All of this major discount is because one patient had a side-effect that is not sure if it is from the drug or from something else. Any little good news and it will triple. WAKE-UP guys !
  • u
    umit
    $ADVM
    why insiders started to sell since last week? Do they know anything about the blind patient`s investigation progress or pre results?
  • A
    Anonymous
    400 mill cash on hand and only 30 mill debt! Why red????
    Bullish
  • R
    RV
    $NTLA conversation
    What did Gene Editing do- took away the sails of several Gene Therapy Drug Companies with Hudred M to over Billion dollar pipelines- Why? Ask this before you sell your stock at a lower price than what you bought for- taking profits is fine with me:

    2021 so far been quite bad year for trad gene tx..

    -from 52 week high (VYGR ADVM both -EV)

    $VYGR -72%
    $ADVM -85%
    $QURE -43%
    $BLUE -54%
    $avro -57%
    $PASG -56%
    $GBIO -53%
    $SRPT -59%
  • g
    gh
    Anyone knows the 4years history of advm?
    Concerned about revenue drop:
    2017 = 1800
    2018 = 1600
    2019 = 250
    2020 = 0
  • M
    Mr. Market
    Cash balance : $442M
    Market cap : $359M
    Price/book : $0.87
    👀
    Bullish
  • S
    Sergio
    The potential of the company is there, in the financial statements and the news. Just sit and wait!
    Bullish
  • q
    qi
    Only 3% higher than 52 wks low. ADVM has kept in $3.4 - $3.8 level for 2 months. Is there any news about AVDM-22 investigation? Is it time for ADVM to bounce back to $7?
  • M
    Mr. Market
    NTLA is a gene-therapy company.
    ADVM is a gene-therapy company.
    Regeneron owns stake in both companies.
    NTLA will explode tomorrow (read today’s news).
    ADVM will EXPLODE soon.
  • f
    fefe
    hidden gem for $3.50 ! Julie Clark, M.D., Promoted to Chief Medical Officer
    As chief medical officer, Dr. Clark will be responsible for clinical strategy and implementation of clinical trials across all phases of development. !!!!!Dr. Clark brings 14 years of experience in clinical development programs and commercial launch initiatives for new therapies for ocular diseases, including !!!!!!Eylea® and BEOVU®!!!!!!. Previously, she !!!!!worked with Novartis!!!! over a five-year period in positions of increasing responsibility. As lead medical director – retina, !!!!!!she was responsible for the Phase 3b clinical trial for BEOVU®!!!!!!and served as medical lead for cross-functional team initiatives for product launch. Earlier, she was medical director, U.S. medical affairs for ThromboGenics, where she supported the Jetrea® launch and late-stage clinical studies. Previously,!!! she worked with Regeneron Pharmaceuticals, Inc!!!!!!, where as associate director, medical affairs – ophthalmology she supported the !!!!!clinical development and commercial launch of Eylea®!!!!!. Before Regeneron, she worked with ISTA Pharmaceuticals as medical affairs product director and helped align strategy and communications for Xibrom®/Bromday®, Bepreve®, Istalol®, Vitrase®. Dr. Clark earned an M.D. from Wake Forest University School of Medicine and a B.S. in Biology from Wake Forest University. In addition, she holds an M.S. in Biotechnology from the Center for Biotechnology Education and Advanced Biotechnology Studies from Johns Hopkins University.
    Bullish